

Faculty Disclosures

Name of Individual	Name of Ineligible Company(s)	Nature of Relationship(s)
Samina Afreen	Tandem Inc.	Research Funding
Monica Agarwal	Chair, Education Committee, The Obesity Society; Board of Directors for NBPNS	Consultant
Aman Rajpal	Obesity Medicine Association	CME Overview Committee
	ABIM Board Exam Item	Writing Task Force
Maria Belalcazar	ABIM Endocrinology and Metabolism Board Exam Item- Writing Task Force	Mentor
	Endocrine Society's Clinical Endocrine Education Committee	Member
Jaydira Del Rivero	NANETS	Guidelines Committee
Alexandra Gangi	ASCO	ASCO NET guidelines
Timothy Garvey	Fractyl Health; Alnylam Pharmaceuticals; Novo Nordisk; Zealand; Merck; Allurion; Inogen; Neurocrine; Carmot/Roche; TERNS Pharmaceuticals; Keros Therapeutics; Regeneron	Advisory Board Consultant
	Boehringer-Ingelheim; Eli Lilly	Advisory Board Consultant; Member of a data monitoring committee

	Eli Lilly; Novo Nordisk; Pfizer; Epitomee; Neurovalens; Zealand; TERNS Pharmaceuticals; and	Research Funding; Site PI for the clinical trials
Marcio Griebeler	Carmot/Roche Novo Nordisk	Site DI for anti-chesity drug
Warcio Griebeier	NOVO NOTAISK	Site PI for anti-obesity drug
Shahnaz Sultan	American Gastroenterological Association	Related Organizations - BOD/ EC Orgs
	US GRADE Network	Related Organizations - BOD/ EC Orgs
Margaret Wierman	Crinetics	Research Funding
Kathleen Wyne	Corcept; Abbvie; Ionis	PI, Research Funding
	National Lipid Association	Appointed to Board of Directors

All of the relevant financial relationships listed for these individuals have been mitigated. All other faculty for this educational activity have no relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.

